Home SpayVac™
for
Wildlife
About
SpayVac™
How
Spayvac™
Works
FDA
Requirements
About
Spayvac.org
FAQ Contact

FDA Requirements

Before it can be made widely available, SpayVac™ must meet FDA requirements. We anticipate that our goal can be reached in 4–5 years, assuming that adequate funding (approx. $5 million ) can be secured in a timely manner and that no serious technical obstacles are encountered.

Good Manufacturing Practice (GMP)
GMP is intended to assure the “identity, strength, quality, and purity” from batch to batch of any vaccine. This is a very demanding requirement, which may require more than $1 million to achieve. GMP must be in place before any of the pivotal trials can be undertaken. This will require 1–2 years to complete.

Adjuvant
Adjuvants are agents that are incorporated into vaccines to stimulate the immune response. The Fallow Deer trials used a SpayVac™ formulation that included Freund’s Complete Adjuvant, a very powerful agent that is used extensively in research but that cannot receive regulatory approval. However, the Penn State trials used SpayVac™ with Adjuvac, an adjuvant developed at the USDA’s National Wildlife Research Center, which has been previously approved. Thus, the final formulation to be taken forward to the FDA will incorporate Adjuvac.

PZP Source
Native PZP, used in SpayVac™ and other IC vaccines, has been routinely obtained as a by-product from slaughterhouses, and this may continue to be the source of PZP for SpayVac™ in the future. However, experiments are underway at the University of Georgia to explore whether recombinant PZP, produced by laboratory bacteria, could replace native PZP. Should recombinant PZP prove effective, both regulatory and manufacturing challenges would be greatly reduced.

FDA Trials
Once a GMP vaccine is available, three types of pivotal trials must be undertaken:

  • Efficacy, to prove independently that SpayVac™ is highly effective,
  • Target-animal safety, to show that SpayVac™ is not harmful to the animals that will be treated, and
  • Human-food safety, to establish in laboratory animals that consuming SpayVac™-treated animals by humans is not harmful.

These trials can be completed in 2–3 years.